Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Reuters

03/20

Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema

Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.
CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.
RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.
Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.
Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2620870037"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620870037\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620870037?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620870037","market":"fut","top_or_hot":-1,"title":"Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        </li>\n<li>\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        </li>\n<li>\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        </li>\n<li>\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        </li>\n<li>\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma &amp; Immunology 2026 Annual Meeting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 18:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        </li>\n<li>\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        </li>\n<li>\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        </li>\n<li>\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        </li>\n<li>\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma &amp; Immunology 2026 Annual Meeting.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL78GY3F:1","article_id":"2620870037","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620870037","pubTimestamp":1774004038,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PHVS":"Pharvaris N.V."},"translate_title":"Pharvaris报告口服deucrictibant治疗遗传性血管性水肿的2期CHAPTER-1和RAPIDe-1试验结果","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHVS":0.9},"content_text":"Pharvaris reports Phase 2 CHAPTER-1 and RAPIDe-1 trial results for oral deucrictibant in hereditary angioedema\n    \n\n\n          Pharvaris reported that two articles in The Lancet Haematology published results from the randomized Phase 2 CHAPTER-1 and RAPIDe-1 studies of deucrictibant, an oral bradykinin B2 receptor antagonist being developed for hereditary angioedema.\n        \n\n          CHAPTER-1 evaluated prophylaxis and showed a statistically significant reduction in attack occurrence versus placebo, with deucrictibant reported as well tolerated at both doses tested.\n        \n\n          RAPIDe-1 evaluated on-demand treatment and showed statistically significant reductions in attack severity versus placebo and reduced time to symptom relief and resolution, with deucrictibant reported as well tolerated at all doses tested.\n        \n\n          Topline data from the Phase 3 CHAPTER-3 prophylaxis study are expected in Q3 2026.\n        \n\n          Confirmatory Phase 3 RAPIDe-3 on-demand data were already presented at the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharvaris NV published the original content used to generate this news brief on March 20, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}